Your browser is no longer supported. Please, upgrade your browser.
Settings
FGEN [NASD]
FibroGen, Inc.
Index- P/E- EPS (ttm)-2.13 Insider Own1.30% Shs Outstand91.17M Perf Week2.60%
Market Cap1.79B Forward P/E- EPS next Y-2.22 Insider Trans-3.86% Shs Float83.64M Perf Month-42.39%
Income-189.30M PEG- EPS next Q-0.80 Inst Own79.80% Short Float10.47% Perf Quarter-50.95%
Sales176.30M P/S10.15 EPS this Y-137.10% Inst Trans4.50% Short Ratio5.61 Perf Half Y-60.51%
Book/sh4.63 P/B4.17 EPS next Y-51.00% ROA-23.10% Target Price- Perf Year-45.42%
Cash/sh7.40 P/C2.61 EPS next 5Y- ROE-43.80% 52W Range18.12 - 57.21 Perf YTD-47.96%
Dividend- P/FCF23.07 EPS past 5Y-8.20% ROI-40.20% 52W High-66.26% Beta1.08
Dividend %- Quick Ratio4.50 Sales past 5Y-0.50% Gross Margin95.00% 52W Low6.51% ATR2.13
Employees599 Current Ratio4.60 Sales Q/Q712.50% Oper. Margin- RSI (14)24.68 Volatility6.00% 6.23%
OptionableYes Debt/Eq0.13 EPS Q/Q43.20% Profit Margin- Rel Volume1.13 Prev Close19.30
ShortableYes LT Debt/Eq0.10 EarningsMar 01 AMC Payout- Avg Volume1.56M Price19.30
Recom2.50 SMA20-31.78% SMA50-49.72% SMA200-53.64% Volume0 Change0.00%
Apr-07-21Downgrade Mizuho Buy → Neutral $72 → $29
Apr-07-21Downgrade H.C. Wainwright Buy → Neutral
Mar-31-21Upgrade BofA Securities Neutral → Buy $47
Mar-02-21Downgrade Jefferies Buy → Hold $75 → $45
Feb-01-21Initiated H.C. Wainwright Buy $58
Oct-26-20Initiated Raymond James Underperform
Jul-10-20Resumed Stifel Buy $71
May-01-20Initiated Cowen Market Perform $40
Apr-27-20Initiated BofA/Merrill Neutral $45
May-29-19Resumed Goldman Neutral
May-10-19Downgrade William Blair Outperform → Mkt Perform
Apr-12-19Initiated Piper Jaffray Neutral $65
Feb-11-19Resumed Stifel Buy $71
Dec-19-18Upgrade Citigroup Neutral → Buy
Aug-08-17Reiterated Stifel Buy $38 → $80
Aug-08-17Reiterated Leerink Partners Outperform $52 → $82
Jul-21-17Downgrade Goldman Buy → Neutral
Jul-11-17Initiated Jefferies Buy
Feb-11-16Upgrade Credit Suisse Neutral → Outperform $40
Jan-21-16Initiated Credit Suisse Neutral
Apr-16-21 09:13AM  
07:59AM  
06:30AM  
06:30AM  
Apr-15-21 10:05PM  
07:33PM  
07:12PM  
07:00PM  
05:40PM  
04:25PM  
04:00PM  
02:31PM  
02:15PM  
02:11PM  
01:45PM  
01:44PM  
12:45PM  
11:41AM  
11:12AM  
11:00AM  
10:00AM  
07:00AM  
06:30AM  
Apr-14-21 11:29PM  
09:00PM  
07:10PM  
06:31PM  
05:00PM  
04:32PM  
04:25PM  
03:30PM  
02:58PM  
02:50PM  
02:07PM  
01:33PM  
12:04PM  
11:50AM  
11:00AM  
10:25AM  
09:39AM  
09:30AM  
06:30AM  
Apr-13-21 09:00PM  
09:00PM  
08:37PM  
08:16PM  
07:24PM  
06:43PM  
05:48PM  
05:44PM  
05:00PM  
04:20PM  
03:55PM  
03:05PM  
03:00PM  
02:52PM  
02:14PM  
11:40AM  
11:00AM  
09:55AM  
08:59AM  
Apr-12-21 03:54PM  
10:05AM  
07:00AM  
Apr-11-21 11:45PM  
Apr-09-21 07:06PM  
01:51PM  
10:50AM  
Apr-08-21 09:00PM  
07:50PM  
06:57PM  
05:00PM  
03:00PM  
02:51PM  
02:06PM  
02:05PM  
01:57PM  
01:37PM  
01:35PM  
11:00AM  
09:39AM  
09:36AM  
09:13AM  
04:30AM  
Apr-07-21 07:59PM  
06:29PM  
05:10PM  
04:44PM  
04:13PM  
04:12PM  
04:00PM  
03:32PM  
02:09PM  
01:56PM  
01:08PM  
11:04AM  
11:00AM  
10:38AM  
09:07AM  
09:00AM  
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KEARNS THOMAS F JRDirectorMar 11Option Exercise3.5018,00063,000166,164Mar 15 06:22 PM
KEARNS THOMAS F JRDirectorMar 11Sale35.0218,000630,360148,164Mar 15 06:22 PM
Kurkijarvi KaleviDirectorFeb 17Option Exercise28.656,000171,90039,100Feb 19 07:10 PM
Kurkijarvi KaleviDirectorFeb 17Sale52.406,000314,38333,100Feb 19 07:10 PM
Kurkijarvi KaleviDirectorJan 19Option Exercise19.056,000114,30039,100Jan 21 07:24 PM
Kurkijarvi KaleviDirectorJan 19Sale43.386,000260,28033,100Jan 21 07:24 PM
Kurkijarvi KaleviDirectorJan 14Option Exercise19.055,999114,28139,099Jan 15 08:02 PM
Kurkijarvi KaleviDirectorJan 14Sale40.045,999240,20033,100Jan 15 08:02 PM
Schoeneck James ADirectorJan 04Option Exercise9.786,00058,65015,400Jan 06 07:08 PM
Kurkijarvi KaleviDirectorDec 28Option Exercise18.346,001110,05939,101Dec 30 06:07 PM
Kurkijarvi KaleviDirectorDec 28Sale40.406,001242,45533,100Dec 30 06:07 PM
Yu K PeonyChief Medical OfficerDec 16Sale41.613,350139,394192,292Dec 17 07:06 PM
Cotroneo PatSVP, Finance and CFODec 15Sale43.603,068133,765266,144Dec 17 07:04 PM
Kouchakji EliasSVP, Clinical Dev, Drug SafetyNov 17Option Exercise14.577,082103,220134,495Nov 19 04:52 PM
Yu K PeonyChief Medical OfficerSep 16Sale44.013,351147,478198,934Sep 18 05:19 PM
Cotroneo PatSVP, Finance and CFOSep 15Sale43.633,070133,944272,226Sep 17 06:03 PM
Cotroneo PatSVP, Finance and CFOSep 03Option Exercise23.3015,004349,582293,314Sep 04 04:30 PM
Yu K PeonyChief Medical OfficerSep 03Option Exercise18.0010,000180,000215,576Sep 04 04:33 PM
Yu K PeonyChief Medical OfficerSep 03Sale50.8910,000508,900205,576Sep 04 04:33 PM
Cotroneo PatSVP, Finance and CFOSep 03Sale50.9115,004763,854278,310Sep 04 04:30 PM
Schoeneck James ADirectorAug 20Option Exercise5.956,00035,70015,400Aug 21 05:58 PM
Cotroneo PatSVP, Finance and CFOAug 11Option Exercise18.727,250135,712278,310Aug 11 04:34 PM
Cotroneo PatSVP, Finance and CFOAug 07Option Exercise19.3922,554437,322293,614Aug 11 04:34 PM
Cotroneo PatSVP, Finance and CFOAug 07Sale48.0022,5541,082,592271,060Aug 11 04:34 PM
Yu K PeonyChief Medical OfficerJul 24Sale42.353,351141,915205,576Jul 28 07:33 PM
Cotroneo PatSVP, Finance and CFOJun 16Sale39.683,928155,863271,060Jun 18 06:35 PM
Conterno Enrique AChief Executive OfficerJun 11Buy35.2819,800698,59927,800Jun 12 06:59 AM
Conterno Enrique AChief Executive OfficerJun 10Buy36.298,000290,2828,000Jun 12 06:59 AM
Rosenkranz Roberto PedroDirectorJun 09Option Exercise23.8524,000572,40096,100Jun 11 09:22 PM